Bioprocessing and manufacturing at Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

87 organizations at Festival of Biologics 2026 present work in bioprocessing & manufacturing: 64 suppliers and service providers, 13 academic, government and non-profit bodies and 10 drug developers. Between them they bring 104 presentations to the program. Most represented: Novartis (29 on the program), Merck KGaA (6 on the program), Lonza (6 on the program). 77 of them have their own page in this guide. As of Sep 26, 2026.

All 378 organizations at Festival of Biologics 2026 →

Showing 1–4 of 87 organizations

Organization	Festival of Biologics 2026 Attendance
Novartis Basel, Switzerland
novartis.com/about/manufacturing/contract-manufacturing Large pharmaGold sponsor Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish.	Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair's Remarks Clinical Trials Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Antibody Keynotes Chair Tue Oct 13 11:25 Chair's Remarks Immunotherapy Keynotes Talk Tue Oct 13 11:30 Cell Line Development: Powering the Biotherapeutics Pipeline, Accelerating Patient Impact Bioprocessing Keynotes Panel Tue Oct 13 12:20 PANEL DISCUSSION: The Next Frontier: Delivering Next-Gen Science for Patients with High Unmet Need Immunotherapy Keynotes · with Memorial Sloan Kettering Cancer Center, STAb Therapeutics, Transgene +1 more Chair Tue Oct 13 14:05 Chair's Remarks Clinical Development & Operations Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 AI for Immunogenicity Prediction of Biologics AI & Computational Approaches Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. with CSEM, HINA Bioventures, Corning Life Sciences Talk Tue Oct 13 15:30 Antibody x Conjugates: ADCs, AOCs and AxCs mAbs Chair Tue Oct 13 16:45 Chair's Remarks Protein Engineering Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. with UCB, FairJourney Biologics, JJP Biologics Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair's Remarks Gene Therapy Chair Wed Oct 14 11:25 Chair's Remarks Downstream Processing Talk Wed Oct 14 11:30 The Good, the Bad and the Aggregated (Solving Protein Purification Mysteries)? Downstream Processing Talk Wed Oct 14 12:10 Introducing PAT into control strategies CMC & Developability Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Title TBA AI & Computational Approaches Chair Wed Oct 14 14:05 Chair's Remarks AI & Computational Approaches Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair's Remarks Disease Areas: Neurodegenerative & CNS Chair Wed Oct 14 16:45 Chair's Remarks Regulated Bioanalysis Talk Wed Oct 14 16:50 The pivotal role of regulated bioanalysis in biotherapeutics development and approval Regulated Bioanalysis Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Scaling the Future of Cell & Gene Therapies: From Scientific Innovation to Sustainable Platforms Manufacturing Chair Thu Oct 15 11:15 Chair's Remarks Fill/Finish Chair Thu Oct 15 11:15 Chair's Remarks Immunogenicity
Merck KGaA Darmstadt, Germany
merckgroup.com Large pharma German science and technology company in healthcare, life science (including bioprocessing products) and electronics.	Chair Tue Oct 13 16:45 Chair's Remarks Upstream Processing Talk Tue Oct 13 17:30 From Fermentation to Vaccination: Non-Animal Origin Squalene for High-Risk Application Formulation Talk Wed Oct 14 11:50 Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities Protein Engineering Talk Wed Oct 14 14:10 Bifunctional antibody derivatives for immune system manipulation Bispecifics & Multispecifics Talk Wed Oct 14 14:10 MCC process implementation - from batch to continuous Downstream Processing Talk Wed Oct 14 15:10 Targeted killing of HER2 overexpressing cells by Single domain antibody-based TNFR1 mimetics Bispecifics & Multispecifics
Lonza Basel, Switzerland
lonza.com CDMO & CROTitle sponsor Contract development and manufacturing partner for biologics, cell and gene therapies and small molecules.	Booth Exhibiting at Booth 450 Talk Tue Oct 13 17:10 De-risking Lyophilization Scale-Up Using predictive models How computer models of freeze-drying can predict what happens at full manufacturing scale, cutting experiments and the risk of a failed transfer. Keynote Wed Oct 14 09:55 From Experimentation to Prediction: How Data-Driven Innovation is Forging Predictability Across Biologics Development and Precision Biomanufacturing Why biologics developers still decide by trial and error, and how treating every program as shared learning could make outcomes more predictable. Bioprocessing & manufacturingAI & computational design Talk Wed Oct 14 12:30 Accelerating CHO Cell Line Development Through Next-Generation Expression System Design How improved cell engineering, promoter design and selection methods shorten the path from DNA to a cell line that makes a drug. Talk Wed Oct 14 14:30 Beyond mAbs: accelerated Gene-to-IND development for bispecifics, Fc-fusions and high-concentration biologics Faster routes from DNA to first clinical trials for complex antibody drugs, and the problems they create in making, purifying and formulating them.
Technical University of Denmark Kongens Lyngby, Denmark
	Talk Tue Oct 13 15:30 Next-generation CHO cell lines for cheaper biosimilar production Upstream Processing Talk Tue Oct 13 17:30 Title TBA Upstream Processing Talk Wed Oct 14 12:10 Insights from Big Data and Novel Platforms to engineer Next Generation of Antibody, Bi-and Multispecific Therapeutics Bispecifics & Multispecifics Talk Wed Oct 14 14:50 Novel platform of glycoengineered sEV for superior drug delivery and gene therapy Gene Therapy Talk Thu Oct 15 11:20 Elimination of CHO clonal variation allows skipping clone screenings Using enzymes called recombinases to insert genes so that cell clones behave almost identically, letting developers skip clone screening entirely.